CLINICAL_TRIALS
trial_result
· 2015-08-20
Clinical Trial Update: Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide [Phase 1]
Summary
Phase 1 pharmacokinetic study assessing the effect of BIA 9-1067 on the PK of repaglinide in Parkinson disease; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bial - Portela C S.A. | Conditions: Parkinson Disease | Phase 1 | Status: COMPLETED | Results posted: 2015-08-20